Intravenous enoxaparin as alternative ECMO anticoagulation over a period of 94 days: a case report
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Intravenous enoxaparin as alternative ECMO anticoagulation over a period of 94 days: a case report ; volume:18 ; number:1 ; day:11 ; month:4 ; year:2023 ; pages:1-4 ; date:12.2023
Journal of cardiothoracic surgery ; 18, Heft 1 (11.4.2023), 1-4, 12.2023
- Urheber
-
Durila, Miroslav
Berousek, Jan
Vlasakova, Vlasta
Vymazal, Tomas
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13019-023-02226-0
- URN
-
urn:nbn:de:101:1-2023082521093465756595
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Durila, Miroslav
- Berousek, Jan
- Vlasakova, Vlasta
- Vymazal, Tomas
- SpringerLink (Online service)
Ähnliche Objekte (12)
Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality
Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO
Between a rock and a hard place: anticoagulation management for ECMO
Anticoagulation during ECMO: Will the Tight Rope be Tighter in 2018?
Comparison of anticoagulation strategies for veno-venous ECMO support in acute respiratory failure
Intravenous immunoglobulin fails to improve ARDS in patients undergoing ECMO therapy
Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial
Enoxaparin-Induced Liver Injury
Use of multiple laboratory tests including anti-factor Xa to optimally manage anticoagulation during ECMO
Anticoagulation
Webinar Anticoagulation
Quo vadis ECMO?
Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality
Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO
Between a rock and a hard place: anticoagulation management for ECMO
Anticoagulation during ECMO: Will the Tight Rope be Tighter in 2018?
Comparison of anticoagulation strategies for veno-venous ECMO support in acute respiratory failure
Intravenous immunoglobulin fails to improve ARDS in patients undergoing ECMO therapy
Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial
Enoxaparin-Induced Liver Injury
Use of multiple laboratory tests including anti-factor Xa to optimally manage anticoagulation during ECMO
Anticoagulation
Webinar Anticoagulation
Quo vadis ECMO?
Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality
Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO
Between a rock and a hard place: anticoagulation management for ECMO
Anticoagulation during ECMO: Will the Tight Rope be Tighter in 2018?
Comparison of anticoagulation strategies for veno-venous ECMO support in acute respiratory failure
Intravenous immunoglobulin fails to improve ARDS in patients undergoing ECMO therapy
Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial
Enoxaparin-Induced Liver Injury
Use of multiple laboratory tests including anti-factor Xa to optimally manage anticoagulation during ECMO
Anticoagulation
Webinar Anticoagulation